D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Materials Science D-index 84 Citations 25,867 144 World Ranking 824 National Ranking 316

Research.com Recognitions

Awards & Achievements

2020 - Fellow, National Academy of Inventors

2018 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

What is he best known for?

The fields of study he is best known for:

  • Enzyme
  • Cancer
  • Biochemistry

His primary areas of study are Nanotechnology, Nanoparticle, Drug delivery, Nanomedicine and Membrane. His work on Coating as part of his general Nanotechnology study is frequently connected to Extramural, thereby bridging the divide between different branches of science. His Nanoparticle research integrates issues from Combinatorial chemistry, Biophysics, Liposome and Particle size.

Liangfang Zhang has researched Drug delivery in several fields, including Ethylene glycol, Cancer research and Cell culture. His work deals with themes such as Human disease and Emerging technologies, which intersect with Nanomedicine. His biological study spans a wide range of topics, including Surface modification and Adsorption.

His most cited work include:

  • Nanoparticles in Medicine: Therapeutic Applications and Developments (1725 citations)
  • Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform (908 citations)
  • Quantum Dot−Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer (755 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Nanotechnology, Nanoparticle, Drug delivery, Membrane and Nanomedicine. His Nanotechnology study combines topics from a wide range of disciplines, such as Cancer cell, Biological fluids and Surface modification. His Nanoparticle research is multidisciplinary, relying on both Liposome, Biophysics, Polymer, Combinatorial chemistry and Dispersity.

His Biophysics study integrates concerns from other disciplines, such as Biochemistry and Intracellular. In his study, Cancer is inextricably linked to Drug, which falls within the broad field of Drug delivery. His Membrane research includes themes of Platelet and Red blood cell.

He most often published in these fields:

  • Nanotechnology (35.42%)
  • Nanoparticle (27.08%)
  • Drug delivery (23.61%)

What were the highlights of his more recent work (between 2017-2021)?

  • Nanotechnology (35.42%)
  • Biophysics (12.85%)
  • Cell biology (8.33%)

In recent papers he was focusing on the following fields of study:

Liangfang Zhang mainly investigates Nanotechnology, Biophysics, Cell biology, Nanomedicine and Membrane. His work in the fields of Nanotechnology, such as Nanoparticle and Nanorobotics, overlaps with other areas such as Micromotor. The various areas that Liangfang Zhang examines in his Biophysics study include Platelet, Extracellular vesicles, Intracellular and Drug.

His research in Cell biology intersects with topics in Epitope, Antimicrobial and Immune system. His Nanomedicine study incorporates themes from Immune modulation and Targeted drug delivery, Drug delivery. His work in Membrane tackles topics such as Cell which are related to areas like Small molecule and In vivo.

Between 2017 and 2021, his most popular works were:

  • Cell Membrane Coating Nanotechnology. (285 citations)
  • Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. (169 citations)
  • Monitoring of the central blood pressure waveform via a conformal ultrasonic device. (159 citations)

In his most recent research, the most cited papers focused on:

  • Enzyme
  • Cancer
  • Biochemistry

His primary areas of study are Nanotechnology, Nanomedicine, In vivo, Membrane and Micromotor. His work deals with themes such as Cancer cell, Cancer treatment and Staphylococcus aureus bacteria, which intersect with Nanotechnology. His Nanomedicine research incorporates themes from Coating, Engineering ethics and Rational design.

The various areas that he examines in his In vivo study include Niche, Regenerative medicine, Biocompatibility, Oxygen delivery and Cell biology. Biological membrane and Cell membrane are among the areas of Membrane where Liangfang Zhang concentrates his study. Liangfang Zhang combines subjects such as Cancer research, Glioma, Drug and Peptide with his study of Drug delivery.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Nanoparticles in Medicine: Therapeutic Applications and Developments

L Zhang;FX Gu;JM Chan;AZ Wang.
Clinical Pharmacology & Therapeutics (2008)

2330 Citations

Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform

Che Ming J. Hu;Li Zhang;Santosh Aryal;Connie Cheung.
Proceedings of the National Academy of Sciences of the United States of America (2011)

995 Citations

Quantum Dot−Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer

Vaishali Bagalkot;Liangfang Zhang;Etgar Levy-Nissenbaum;Sangyong Jon.
Nano Letters (2007)

982 Citations

Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform.

Liangfang Zhang;Juliana M. Chan;Frank X. Gu;June Wha Rhee.
ACS Nano (2008)

779 Citations

Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.

Frank Gu;Liangfang Zhang;Benjamin A. Teply;Nina Mann.
Proceedings of the National Academy of Sciences of the United States of America (2008)

768 Citations

Development of Nanoparticles for Antimicrobial Drug Delivery

Zhang L;Pornpattananangku D;Hu Cm;Huang Cm.
Current Medicinal Chemistry (2010)

696 Citations

PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery.

Juliana M. Chan;Liangfang Zhang;Kai P. Yuet;Grace Liao.
Biomaterials (2009)

639 Citations

Nanoparticle biointerfacing by platelet membrane cloaking

Che Ming J. Hu;Ronnie H. Fang;Kuei Chun Wang;Brian T. Luk.
Nature (2015)

604 Citations

Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery

Ronnie H. Fang;Che-Ming J. Hu;Brian T. Luk;Weiwei Gao.
Nano Letters (2014)

563 Citations

Nanoparticle-based combination therapy toward overcoming drug resistance in cancer

Che-Ming Jack Hu;Liangfang Zhang.
Biochemical Pharmacology (2012)

510 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Liangfang Zhang

Omid C. Farokhzad

Omid C. Farokhzad

Harvard Medical School

Publications: 120

Joseph Wang

Joseph Wang

University of California, San Diego

Publications: 83

Robert Langer

Robert Langer

MIT

Publications: 64

Martin Pumera

Martin Pumera

Brno University of Technology

Publications: 63

Oliver G. Schmidt

Oliver G. Schmidt

Leibniz Institute for Solid State and Materials Research

Publications: 54

Xiaoyuan Chen

Xiaoyuan Chen

National University of Singapore

Publications: 46

Mauro Ferrari

Mauro Ferrari

Houston Methodist

Publications: 45

Zhen Gu

Zhen Gu

Zhejiang University

Publications: 41

Qiang He

Qiang He

Harbin Institute of Technology

Publications: 40

Wei Gao

Wei Gao

California Institute of Technology

Publications: 40

Weihong Tan

Weihong Tan

Hunan University

Publications: 39

Xian-Zheng Zhang

Xian-Zheng Zhang

Wuhan University

Publications: 38

Hélder A. Santos

Hélder A. Santos

University of Helsinki

Publications: 36

Yaping Li

Yaping Li

Chinese Academy of Sciences

Publications: 33

Xing-Jie Liang

Xing-Jie Liang

Chinese Academy of Sciences

Publications: 30

Kang Zhang

Kang Zhang

Sichuan University

Publications: 30

Something went wrong. Please try again later.